Prognostic significance of cell-cycle regulatory proteins for outcome after primary radiochemotherapy in patients with advanced head and neck cancer;Expression von zellzykluskomponenten in fortgeschrittenen kopf-hals- karzinomen. Bedeutung fur die prognose nach primarer akzelerierter radiochemotherapie

HNO

Volumn 47, Issue 9, 1999, Pages 777-786

  Haas, S ^a   Bosch, F X ^a   Klein Kuhne W ^a   Nollert, J ^a   Rudat, V ^a   Conradt, C ^a   Dietz, A ^a  

^a NONE

Author keywords

Cell cycle regulatory proteins; Head and neck tumors; Prognostic factors; Radiochemotherapy

Indexed keywords

CARBOPLATIN; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHASE 2 CLINICAL TRIAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; COMBINED MODALITY THERAPY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PILOT PROJECTS; PROGNOSIS; RADIOTHERAPY DOSAGE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032827609     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001060050460     Document Type: Article

References (24)

1. Ahomadegbe JC, Barrois M, Fogel S et al. (1995) High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10:1217-1227
2. Andl T, Kahn T, Pfuhl A et al. (1998) Etiological involvement af oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58:5-13
3. Dietz A, Rudat V, Nollert J et al. (1996) Akzelerierte hyperfraktionierte simultane Radiochemotherapie bei fortgeschrittenen Kopf-Halskarzinomen im Vergleich: split-course und concomitant-boost Konzept. Laryngorhinootologie 75:45-753
4. El-Deiry WS, Tokino T, Velescu VE et al. (1993) WAF 1, a potenial mediator of p53 tumor-suppression. Cell 75:817-825
5. Erber R, Conradt C, Homann N et al. (1998) TP53 DNA contact mutations are selectively associated with allelic loss and have strong clinical impact in head and neck cancer. Oncogene 16:1671-1679
6. CIP1/WAF1 protein accumulation in head- and neck-cancer, Int J Cancer 74:383-389
7. Gasparini G, Bevilacqua P, Bonoldi E et al. (1995) Prognostic and predictive markers in a series of patients with head and neck squamous cell carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1:1375-1383
8. Hall PA, Woods AL (1990) Immunohistochemical markers of cellular proliferation: achievments, problems, prospects. Cell Tissue Kinet 23:505-522
9. Horiot JC, Bontemps P, van den Bogaert W et al. (1997) Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44:111-121
10. HunterT, Pines J (1994) Cyclines and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582
11. Kamb A, Gruis NA, Weaver-Feldhaus J et al. (1994a) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440
12. Lee JM, Bernstein A (1993) p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90:5742-5746
13. Lukas J, Parry D, Aagaard L et al. (1995) Retinoblastoma-protein-dependent cell cycle inhibition by the tumor suppressor p16. Nature 375:503
14. Michalides RJ, van Veelen NM, Hart AA, Loftus BM, Hilgers FJ, Balm AJ (1997) Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 123:497-502
15. 1/S-cyclins and cyclin dependent kinases chrarkterize squamous cell carcinomas of the head and neck. Int J Cancer 73:551-555
16. Preisler V, Kirchner S, Hagen R (1997) Zur klinischen Bedeutung des Tumorsuppressorgens p53 bei Kopf-Hals-Tumoren. HNO 45:659-662
17. Raybaud-Diogène, Fortin A, Morency R, Roy J, Monteil RA, Têtu B (1997) Markers of radio-resistence in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol 15:1030-1038
18. Reed MF, Liu VF, Ladha MH, Kiyoshi A, Griffin JD, Weaver DT, Ewen ME (1998) Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation. Oncogene 17:2961-2971
19. Schrader M, Schipper J, Jahnke K, Stuschke M, Sack H, Budach V (1998) Hyperfraktionierte-akzelerierte simultane Radio-Chemo-Therapie bei fortgeschrittenen Hypopharynxkarzinomen. HNO 46:140-145
20. Sellers WR, Kaelin WG (1997) Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 15:3301-3312
21. Shin DM, Jin SL, Lippman SM et al. (1996) p53 expression: predicting recurrence in second primary tumors in head and neck squamous neck carcinoma. J Nat Cancer Inst 88:519-529
22. Taylor SG 4th, Murthy AK, Griem KL et al. (1997) Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results. Head Neck 19:684-691
23. Wood NB, Kotelnikov V, Caldarelli DD et al. (1997) Mutation of p53 in squamous cell cancer of the head and neck: relationship to tumor cell proliferation. Laryngoscope 107:827-833
24. Wustrow TPU (1998) Überlegungen zur simultanen Radio-Polychemotherapie bei Kopf-Hals-Karzinomen. HNO 46:92-94